Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease

The prevalence of type 2 diabetes (T2D) continues to increase, and its association with cardiovascular (CV) disease has led to the inclusion of CV endpoints in clinical trials on the treatment of T2D. This article explores the various trials already performed and under development in this field, wit...

ver descrição completa

Detalhes bibliográficos
Autor principal: Monteiro, P (author)
Outros Autores: Aguiar, C (author), Matos, P (author), Silva-Nunes, J (author), Birne, R (author), Branco, P (author), Calado, J (author), Melo, M (author), Polónia, J (author)
Formato: article
Idioma:eng
Publicado em: 2020
Assuntos:
Doenças Cardiovasculares
Diabetes Mellitus Tipo 2
Empagliflozina
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Empagliflozin
Texto completo:http://hdl.handle.net/10400.26/30991
País:Portugal
Oai:oai:comum.rcaap.pt:10400.26/30991

Texto Completo

http://hdl.handle.net/10400.26/30991

Registos relacionados